ArticleThe Veterinary record2026
Evaluation of thyroglobulin autoantibodies in dogs at the time of diagnosis of hypoadrenocorticism and during treatment.
Article in The Veterinary record, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune thyroiditis (AIT) may occur more frequently in dogs with hypoadrenocorticism (HA) than previously recognised. The objective of this study was to determine the presence of thyroglobulin autoantibodies (TgAAs) in dogs with HA.
methodsDogs were included if HA was confirmed by an adrenocorticotropic hormone stimulation test conducted between 2019 and 2023. Serum total thyroxine, thyrotropin and TgAA were analysed from samples taken before and during HA treatment.
resultsThirty-seven dogs were enrolled, with nine dogs showing positive TgAA titres at enrolment. Following HA treatment, TgAA became undetectable in six dogs; two showed persistent positive TgAA results and one was lost to follow-up. Additionally, two dogs that were initially TgAA negative developed hypothyroidism during the follow-up period. The overall prevalence of concurrent HA and hypothyroidism after initiation of hormone replacement therapy was three of 30 among the dogs for which follow-up data were available. LIMITATIONS: The retrospective nature of the study, small sample size and incomplete follow-up data for some patients limit the conclusions that can be drawn.
conclusionOur findings demonstrate the concurrent occurrence of two different autoimmune diseases, AIT and HA, and show that the presence of TgAA can completely resolve with cortisol replacement therapy. Therefore, it is recommended to reassess thyroid function after initiating HA treatment to avoid unnecessary lifelong thyroxine supplementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.